Investing.com UK - Financial Markets Worldwide
Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates

Published 04/10/2022, 17:56
Updated 04/10/2022, 18:41
© Reuters. Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
VIR
-

  • With its COVID-19 monoclonal antibody sidelined in the U.S. since April and plans for full approval no longer in the cards, Vir Biotechnology Inc (NASDAQ: VIR) is focusing on influenza product.
  • U.S. Department of Health and Human Services' BARDA has injected $55 million into the company's asset, dubbed VIR-2482, with the potential for up to $1 billion to advance the development across that program and others.
  • As part of the multi-year contract, Vir could be on tap to create as many as ten candidates — whether mAbs or other modalities — for emerging infectious diseases or Chemical, Biological, Radiological, and Nuclear medical countermeasures.
  • Also see: WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete.
  • The federal government concocted a 12-option agreement with the biotech.
  • Rajesh Gupta, VP, global health portfolio and public-private partnerships at Vir, said, "We are proud to have contributed to the fight against COVID-19 with the delivery of sotrovimab, and to have helped address Ebola with the co-discovery of ansuvimab-zykl. We now look forward to applying our scientific and executional expertise to this BARDA collaboration focused on advancing innovative solutions to influenza, as well as other infectious diseases with future pandemic potential."
  • Price Action: VIR shares are up 5.81% at $21.12 on the last check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.